EverBridge Medical Group Secures Over RMB 1 Billion in Series A Funding Led by CBC Group

China.com.cn Finance, March 25 — Today, EverBridge Group announced the completion of its Series A financing round, with the amount raised exceeding RMB 1 billion.

This round of financing was led by CBC Group, with participation from the Beijing Pharmaceutical and Health Industry Investment Fund and Beishou Capital. The funds will support EverBridge Group in accelerating product development and commercialization strategies, further solidifying its leading position in the field of innovative treatments for high-prevalence chronic diseases.

Data indicates that EverBridge Group is a leading medical technology group in Asia. Leveraging the research capabilities of its “Institute for Frontier Medical Technologies” and the technological infrastructure of its “Six Shared Core Technology Centers,” the company has successfully achieved “zero-to-one” R&D value creation in the integrated fields of peripheral vascular disease, neuroscience, and oncology diagnosis and treatment. Furthermore, supported by the lean value management system of its “EBSTM Excellence System,” EverBridge has realized “one-to-N” multiplicative growth in commercial value.

Through this round of financing, EverBridge Group will increase its investment in R&D innovation to promote new product development and technological breakthroughs, while expanding into new clinical treatment areas. Meanwhile, the Group will further expand its production scale to enhance capacity and supply chain efficiency. In terms of global strategy, EverBridge Group will adopt a dual approach of “bringing in” and “going out”—collaborating with top multinational corporations, innovative enterprises, and channel partners to explore international markets, introducing global innovations into China’s healthcare system, particularly penetrating grassroots medical markets, and providing accessible and affordable innovative healthcare solutions for medical institutions and patients worldwide.

Lu Yanxiang, Senior Managing Director at CBC Group and Head of Equity Investment as well as Medical Device and Services Investment, stated that against the backdrop of accelerating global innovation in medical technology, EverBridge Group is redefining the innovation model of China’s medical device industry with its unique platform advantages and exceptional R&D capabilities. “This round of financing will help the Group develop more breakthrough products, reduce the R&D costs of innovative medical devices, and achieve high-quality, inclusive healthcare. This will not only drive the Chinese medical device industry toward higher-level development but also bring more accessible and affordable innovative healthcare solutions to patients worldwide.”

“As the fund manager of the Beijing Medical and Health Industry Investment Fund, we prioritize the medical device sector. While the industry faces challenges at this stage, it also holds tremendous opportunities,” said a representative from Shunxi Fund. The representative expressed confidence that the platform-based advantages and characteristics of EverBridge Group would effectively integrate the highly fragmented medical device market, promote the deep integration of technological innovation with commercialization, and significantly enhance corporate innovation and competitiveness. This will not only drive innovative development in China’s medical device industry but also ensure that innovative technologies and products benefit more medical institutions and patients.

A representative from Beishou Capital stated that, as the manager of the Daxing Development Guidance Fund, Beishang Capital actively participated in co-investing in this round of financing. Under the guidance and support of the Daxing District State-owned Assets Supervision and Administration Commission (SASAC) and relevant authorities, the Daxing Development Guidance Fund has formulated an investment strategy centered on “hard technology” and focused on dominant industries, with pharmaceuticals and healthcare currently representing the largest share of its investment portfolio. “Our participation in the investment in EverBridge Group is driven by its strong R&D innovation capabilities and overseas expansion potential. We aim to not only drive economic development in the Daxing district but also facilitate the global expansion of outstanding Chinese enterprises and innovative products, thereby establishing a new hallmark of ‘Intelligent Manufacturing in China.’”

Wang Jian, CEO of EverBridge Group, stated that at the new stage of accelerated innovation in the medical technology industry, the Group will fully leverage this financing opportunity, relying on the Group’s unique EBS^™The Excellence System’s “1+X” competency model, in conjunction with two frontier technology research institutes focused on “passive materials” and “active intelligence,” continuously strengthens R&D innovation capabilities. By integrating the Group’s traditional advantage products with critical breakthroughs in bottleneck material processes, artificial intelligence, and robotics, it persistently explores new therapeutic areas to provide innovative solutions for physicians and patients. “We will further refine our lean operational system, accelerate the commercialization of our products in both domestic and international markets, and consolidate our leading position in innovative treatments for high-prevalence chronic diseases, thereby delivering more innovative, high-quality, and accessible healthcare solutions to patients in China and around the world.”